BR112017010718A2 - polinucleotídeo otimizado por códon para expressão de alto nível de crm197 - Google Patents
polinucleotídeo otimizado por códon para expressão de alto nível de crm197Info
- Publication number
- BR112017010718A2 BR112017010718A2 BR112017010718A BR112017010718A BR112017010718A2 BR 112017010718 A2 BR112017010718 A2 BR 112017010718A2 BR 112017010718 A BR112017010718 A BR 112017010718A BR 112017010718 A BR112017010718 A BR 112017010718A BR 112017010718 A2 BR112017010718 A2 BR 112017010718A2
- Authority
- BR
- Brazil
- Prior art keywords
- crm197
- high level
- level expression
- polynucleotide
- optimized polynucleotide
- Prior art date
Links
- 108091033319 polynucleotide Proteins 0.000 title abstract 5
- 102000040430 polynucleotide Human genes 0.000 title abstract 5
- 239000002157 polynucleotide Substances 0.000 title abstract 5
- 108010071134 CRM197 (non-toxic variant of diphtheria toxin) Proteins 0.000 title abstract 4
- 230000014509 gene expression Effects 0.000 title abstract 4
- 108020004705 Codon Proteins 0.000 title 1
- 238000000034 method Methods 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
- 108700012359 toxins Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
Abstract
resumo "polinucleotídeo otimizado por códon para expressão de alto nível de crm197? a presente invenção se refere à expressão de alto nível de toxoide bacteriano ou proteína de toxina de interesse farmacológico por meio de uma sequência de polinucleotídeo novo otimizado e hospedeiro transformado com o polinucleotídeo. especificamente, a invenção provê um método para produção elevada de crm197 de polipeptídio em que o polinucleotídeo da invenção é usado para transformar um hospedeiro adequado resultando em superexpressão de proteínas correspondentes e um método para isolar o polipeptídio expresso. mais particularmente, a presente invenção refere-se à expressão de alto nível de crm197 em escherichia coli e um método para o isolamento e purificação do mesmo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN4045CH2014 | 2014-11-20 | ||
PCT/IN2015/000427 WO2016079755A1 (en) | 2014-11-20 | 2015-11-17 | Codon optimized polynucleotide for high level expression of crm197 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017010718A2 true BR112017010718A2 (pt) | 2017-12-26 |
Family
ID=55346156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017010718A BR112017010718A2 (pt) | 2014-11-20 | 2015-11-17 | polinucleotídeo otimizado por códon para expressão de alto nível de crm197 |
Country Status (12)
Country | Link |
---|---|
US (1) | US10280409B2 (pt) |
EP (1) | EP3221339A1 (pt) |
JP (2) | JP2017538444A (pt) |
CN (1) | CN107109416A (pt) |
AU (1) | AU2015348922B2 (pt) |
BR (1) | BR112017010718A2 (pt) |
CA (1) | CA2968491C (pt) |
EA (1) | EA035117B1 (pt) |
MX (1) | MX2017006506A (pt) |
SA (1) | SA517381488B1 (pt) |
WO (1) | WO2016079755A1 (pt) |
ZA (1) | ZA201703150B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107810010A (zh) | 2015-06-23 | 2018-03-16 | 生物E有限公司 | 多价肺炎球菌结合疫苗 |
UA126385C2 (uk) | 2016-09-30 | 2022-09-28 | Байолоджикал І Лімітед | Композиції полівалентної пневмококової вакцини, що містять кон'югати полісахарид-білок |
WO2019043593A1 (en) * | 2017-09-01 | 2019-03-07 | Lorven Biologics Private Limited | NUCLEIC ACID ENCODING CRM197 AND ENHANCED EXPRESSION PROCESS THEREOF |
CN112513066A (zh) * | 2018-01-19 | 2021-03-16 | 台湾浩鼎生技股份有限公司 | Crm197蛋白质表达 |
WO2020033398A1 (en) * | 2018-08-06 | 2020-02-13 | The Trustees Of Columbia University In The City Of New York | Compositions and methods for treating atii cell-dependent lung diseases |
KR102142255B1 (ko) * | 2019-12-05 | 2020-08-07 | 주식회사 제노포커스 | Crm197 단백질 발현 방법 |
GB202108650D0 (en) * | 2021-06-17 | 2021-08-04 | Inst De Medicina Molecular Joaeo Lobo Antunes | Production of cross-reactive material 197 fusion proteins |
KR20230102682A (ko) * | 2021-12-30 | 2023-07-07 | (주)셀트리온 | 목적 단백질의 발현 방법 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4755465A (en) | 1983-04-25 | 1988-07-05 | Genentech, Inc. | Secretion of correctly processed human growth hormone in E. coli and Pseudomonas |
US5281532A (en) | 1983-07-27 | 1994-01-25 | Mycogen Corporation | Pseudomas hosts transformed with bacillus endotoxin genes |
US4695462A (en) | 1985-06-28 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of biological pesticides |
US4695455A (en) | 1985-01-22 | 1987-09-22 | Mycogen Corporation | Cellular encapsulation of pesticides produced by expression of heterologous genes |
US5128130A (en) | 1988-01-22 | 1992-07-07 | Mycogen Corporation | Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens |
US5055294A (en) | 1988-03-03 | 1991-10-08 | Mycogen Corporation | Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens |
US5169760A (en) | 1989-07-27 | 1992-12-08 | Mycogen Corporation | Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters |
ES2231770T3 (es) | 1993-03-05 | 2005-05-16 | Wyeth Holdings Corporation | Nuevos plasmidos para la produccion de proteina crm y toxina difterica. |
US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
CN101378778B (zh) * | 2005-12-22 | 2013-02-06 | 葛兰素史密丝克莱恩生物有限公司 | 肺炎球菌多糖缀合物疫苗 |
IT1398927B1 (it) | 2009-06-25 | 2013-03-28 | Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi | Espressione batterica di un gene artificiale per la produzione di crm197 e derivati. |
GB0917647D0 (en) * | 2009-10-08 | 2009-11-25 | Glaxosmithkline Biolog Sa | Expression system |
CA2793978C (en) | 2010-03-30 | 2021-08-03 | Pfenex Inc. | High level expression of recombinant toxin proteins |
GB201106225D0 (en) | 2011-04-13 | 2011-05-25 | Glaxosmithkline Biolog Sa | Fermentation process |
GB201209896D0 (en) | 2012-06-01 | 2012-07-18 | Fujifilm Diosynth Biotechnologies Uk Ltd | Process |
CN102766647A (zh) * | 2012-07-25 | 2012-11-07 | 天津康希诺生物技术有限公司 | 在白喉杆菌中稳定复制的表达载体及含该载体的白喉杆菌 |
JP2016501550A (ja) * | 2012-12-27 | 2016-01-21 | グリコヴァキシン アーゲー | Crm197に関する方法及び組成物 |
CN103266125A (zh) * | 2013-06-04 | 2013-08-28 | 北京民海生物科技有限公司 | 白喉毒素突变体crm197的制备方法 |
AU2015225439B2 (en) | 2014-03-03 | 2020-12-17 | Scarab Genomics, Llc | Enhanced production of recombinant CRM197 in E. coli |
-
2015
- 2015-11-17 WO PCT/IN2015/000427 patent/WO2016079755A1/en active Application Filing
- 2015-11-17 JP JP2017546275A patent/JP2017538444A/ja active Pending
- 2015-11-17 US US15/523,616 patent/US10280409B2/en active Active
- 2015-11-17 EA EA201791118A patent/EA035117B1/ru unknown
- 2015-11-17 BR BR112017010718A patent/BR112017010718A2/pt active IP Right Grant
- 2015-11-17 EP EP15832894.8A patent/EP3221339A1/en active Pending
- 2015-11-17 AU AU2015348922A patent/AU2015348922B2/en active Active
- 2015-11-17 MX MX2017006506A patent/MX2017006506A/es unknown
- 2015-11-17 CA CA2968491A patent/CA2968491C/en active Active
- 2015-11-17 CN CN201580062524.6A patent/CN107109416A/zh active Pending
-
2017
- 2017-05-08 ZA ZA2017/03150A patent/ZA201703150B/en unknown
- 2017-05-09 SA SA517381488A patent/SA517381488B1/ar unknown
-
2020
- 2020-07-03 JP JP2020115624A patent/JP7042305B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP2017538444A (ja) | 2017-12-28 |
JP2020171307A (ja) | 2020-10-22 |
EA035117B1 (ru) | 2020-04-29 |
AU2015348922B2 (en) | 2020-01-23 |
JP7042305B2 (ja) | 2022-03-25 |
ZA201703150B (en) | 2019-05-29 |
US10280409B2 (en) | 2019-05-07 |
EP3221339A1 (en) | 2017-09-27 |
WO2016079755A1 (en) | 2016-05-26 |
US20170306302A1 (en) | 2017-10-26 |
CA2968491C (en) | 2023-09-26 |
AU2015348922A8 (en) | 2019-03-14 |
CN107109416A (zh) | 2017-08-29 |
AU2015348922A1 (en) | 2017-06-01 |
EA201791118A1 (ru) | 2017-10-31 |
SA517381488B1 (ar) | 2021-10-17 |
MX2017006506A (es) | 2018-03-12 |
CA2968491A1 (en) | 2016-05-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017010718A2 (pt) | polinucleotídeo otimizado por códon para expressão de alto nível de crm197 | |
MX2019013331A (es) | Sistemas de produccion recombinante para policetidos prenilados de la familia de los cannabinoides. | |
BR112016002614A8 (pt) | Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica | |
BR112018011073A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes e métodos de utilização | |
PH12016501671B1 (en) | Novel polysaccharide and uses thereof | |
BR112017006736A2 (pt) | anticorpos antimiostatina, polipeptídeos contendo regiões fc variantes, e métodos de utilização | |
BR112016005228A8 (pt) | Uso de uma ou mais glicosidases e processo para produzir um oligossacarídeo | |
BR112013026175A2 (pt) | proteína de fusão, composição imunogênica, vacina, uso das referidas proteína de fusão, composição imunogênica ou vacina, e, processo para produzir expressão periplasmática de uma proteína de fusão | |
BR112012019404B8 (pt) | Método para a preparação de moléculas de anticorpos recombinantes | |
BR112016012024A2 (pt) | vacina contra colibacilose | |
BR112017020561A2 (pt) | transaminase mutante, proteína, ácido nucleico, célula hospedeira, método de produção de amina e uso de transaminase mutante | |
BR112017009545A2 (pt) | composição antibacteriana, método para a preparação de uma composição, bacteriófago, ácido nucleico isolado, polipeptídeo isolado, e uso de um bacteriófago, ácido nucleico ou polipeptídeo | |
BR112017010010A2 (pt) | método para produzir 3-oxo-5-hidroxipentanoil-coa, método para biossintetizar 1,3-butanodiol, hospedeiro recombinante, produto bioderivado, produto biobaseado ou produto derivado de fermentação, retícula bioquímica de ocorrência não natural, construto de ácido nucleico ou vetor de expressão e composição | |
BR112016016342A2 (pt) | Polipeptídeo variante que tem atividade de lactase, sequência de ácido nucleico, construto de ácido nucleico, vetor de expressão recombinante, método para produzir uma lactase, método para produzir uma variante de polipeptídeo de lactase, composição, uso de um polipeptídeo variante, processo para a produção de um produto lácteo e produto lácteo | |
BR112017020308A2 (pt) | udp-glicosiltransferases | |
BR112016007182A2 (pt) | método para produzir um l-aminoácido | |
MX2018007325A (es) | Promotor de catalasa modificado bidireccional de bacilo. | |
BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
BR112016025898A2 (pt) | ?drimenol sintases e método para produzir drimenol? | |
BR112016011095A2 (pt) | Sequência de endolisina el188 modificada | |
BR112016016103A2 (pt) | Composição de antígenos micobacterianos | |
MX2022009064A (es) | Procedimiento para preparar una composicion de consome que puede ser bombeada. | |
BR112016015812A2 (pt) | Método para aumentar a biomassa e o conteúdo lipídico em um microrganismo e um microrganismo geneticamente modificado exibindo autofagia reforçada | |
BR112018012193A2 (pt) | variantes do polipeptídeo de fusão relacionados à ômega-hidroxilase com propriedades melhoradas | |
MX2015012605A (es) | Procedimiento para preparar una composición de consomé. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/11/2015, OBSERVADAS AS CONDICOES LEGAIS |